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Agricultural pesticides are an important 
component of intensive agriculture and, 
therefore, of global food production. In the 
European Union, approximately 500 active 
substances used in pesticides are currently 
approved, including insecticides, fungicides, 
herbicides, and plant growth regulators. 
When used at industrial scales, pesticides 
can harm the environment (1), but there is a 
trade-off between this effect and the need 
to produce food. Recent uncertainties about 
the health and environmental effects of 
glyphosate herbicide and neonicotinoid 
insecticides underline the need for 
regulation to be sensitive to this trade-off (2, 
3). Better regulation is needed to control 
how pesticides are used and affect the 
environment at a landscape scale.  
 
Important insights into how pesticides can 
be better regulated come from the 
regulation and monitoring of 
pharmaceuticals. In particular, antibiotics 
provide some intriguing parallels with 
pesticides. Society depends on pesticides in 
a similar way to how it relies on antibiotics. 
Both have been manufactured and supplied 
to market demand with little care taken to 
consider whether this is sensible. Both are 
often used prophylactically or as therapies 
of first resort, when sparing use would be 
more appropriate. Both are vulnerable to 
loss of efficacy because of resistance in 
target organisms. And, in both cases, there 
are market failures in supply because of the 
costs of market entry (4–6). This cost is 
mainly driven by the need to sustain high 
standards of safety, including 
environmental safety in the case of 
pesticides. There is now a global effort to 
resolve the problem of loss of effective 
antibiotics. We suggest that more effective 
global governance of pesticides and their 
use is also needed.  
 
Standard environmental toxicity tests used 
to license pesticides are performed on 
particular test species and have limited 
predictive power when chemicals are used 
widely. Diffuse environmental effects that 
arise from ecosystem connectivity at a 
landscape scale are hard to measure but 
may still be appreciable. There is a low level 
of trust in current toxicology testing regimes 
because they are unable to encompass the 
full range of toxic effects that could emerge 
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when used at scale. This is resulting in 
precautionary regulation and the gradual 
withdrawal of key pesticides from the 
market (7). The withdrawal of pesticides will 
incentivize innovations, including changes 
to the crops grown, cultivation methods, 
and new types of pesticides. However, the 
abrupt withdrawal of pesticides may lead to 
the use of alternatives which can be just as 
problematic. Agricultural systems need 
time to adapt, and regulation can help to 
make the use of a pesticide more 
proportionate to the trade-off between 
costs and benefits.  
 
How can this be achieved? Comparison with 
the regulation of pharmaceuticals may help 
to find an answer (see the table). The 
pharmaceutical and pesticide industries 
both seek bioactive chemicals with dose- 
and species-dependent effects. However, 
governance and vigilance (continued 
surveillance for indicators of negative 
effects) of pharmaceuticals and pesticides 
differ widely once market authorization has 
been granted.  
 
The overarching principle for 
pharmaceutical governance is to ensure 
that medicines are effective, safe, and 
marketed on the basis of need. Regulation, 
under the global governance of the World 
Health Organization (WHO), aims to 
balance encouraging the development and 
appropriate use of new medicines and 
preventing the use of ineffective or harmful 
ones.  
 
By contrast, there is no global governance 
for pesticides, and national pesticide 
standards vary around the world (8, 9). 
International harmonization of pesticide 
registration procedures is being attempted 
through the OECD Agricultural Pesticide 
Programme. Member countries are 
encouraged to harmonize methods to 
assess, report, and reduce the risks from 
pesticides. The United Nations (UN) Food 
and Agriculture Organization (FAO) 
International Code of Conduct on Pesticide 
Management, which was introduced in 1985 
and revised most recently in 2014, sets 
voluntary standards for the management of 
pesticides in national legislation (10). 
However, implementation varies greatly 
between countries (11, 12). In most 
developed countries, approval of a 
substance requires an extensive dossier of 
evidence, but developing countries often 
lack the expertise to assess this evidence 
and have lower standards of 
implementation and enforcement (8, 12).  
 
Pharmaceuticals that pass preclinical 
testing for safety and efficacy undergo three 
phases of trials (Phases I to III) with 
increasing patient numbers. These trials are 
designed to test effectiveness, determine 
safety, and identify side effects before 
marketing approval is sought. A fourth 
phase, Phase IV, begins once a product has 
been licensed and involves long-term safety 
monitoring of the product to reveal 
unexpected untoward effects when used at 
large scale. This long-term monitoring — 
termed pharmacovigilance — involves the 
collection, detection, assessment, 
monitoring, and prevention of adverse 
effects of pharmaceutical products. It 
continues throughout the lifetime of each 
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product, building a well-developed safety 
database for that product. 
Pharmacovigilance reporting systems such 
as the Yellow Card System (United 
Kingdom), EudraVigilance (European 
Union), the FDA Adverse Event Reporting 
System (United States), and VigiBase 
(global) are linked to the WHO Programme 
for International Drug Monitoring.  
 
For pesticides, the process of substance 
discovery and early testing is similar. There 
are no defined phases equivalent to the 
phases I to III used for medicines, but a 
similar process tests for effectiveness, 
toxicology, fate, and behaviour in the 
environment using a combination of 
laboratory (in vitro and in vivo) and field 
trials. If approved by the regulatory 
authority, the product can be used in 
accordance with the label for the duration of 
the license (typically 10 to 15 years in the 
European Union and 15 years in the United 
States).  
 
However, there is no equivalent post-
marketing mechanism to 
pharmacovigilance and no equivalent of 
Phase IV. Some post-license vigilance is 
present for protecting human health from 
the effects of pesticides. Food is monitored 
for maximum residue levels (MRLs) to help 
protect human health from the effects of 
consuming pesticides, but international 
MRLs vary widely. The Codex Alimentarius 
Commission sets nonbinding MRLs that can 
be adopted by countries with no agreed-
upon MRLs, but there is no global 
harmonization of levels. This could mean 
that foods exceeding MRLs in one country 
can be exported to countries with 
inadequate sampling or lower standards (8).  
Pharmacovigilance on the scale that is 
required for medicines does not exist to 
assess the effects of pesticides in the 
environment. The FAO recommends that 
countries report pesticide use, but this 
reporting normally only provides 
information about the total amount of any 
pesticide used annually, the total area of 
land treated with pesticides, and the range 
of crops treated. In countries without 
dedicated monitoring, pesticide sales 
statistics are used as a less accurate proxy. 
Reporting systems for incidents involving 
spills, livestock or wild animal deaths, or 
other effects of pesticide use are also 
lacking in many countries (12, 13). 
Regulation in the European Union and the 
United States requires that pesticide 
authorization holders submit new 
information on potentially dangerous 
effects of a pesticide on human or animal 
health, ground water, or the environment, 
but it is often not clear what they should be 
measuring and reporting; the onus is on the 
user to make a judgment about what is 
worth reporting, and compliance is rarely 
enforced effectively.  
 
In some countries, such as the United 
Kingdom, other European Union member 
states, and the United States, all reported 
pesticide incidents involving people, wildlife, 
or the environment are investigated, but 
there is no equivalent to the Yellow Card, 
EudraVigilance, or VigiBase systems to 
monitor the environmental effects of 
pesticides during normal use. There is also 
no estimate of the number of incidents that 
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go unreported and that are therefore not 
investigated. Monitoring and preventing 
misuse, accidents, and unintended effects 
of pesticides requires investment in 
organizational design for information 
collection and processing, which is absent in 
most countries.  
 
The United Kingdom has one of the most 
developed regulatory and monitoring 
systems for pesticides. Yet, it has no 
systematic monitoring of pesticide residues 
in the environment, and no equivalent to 
MRL in foods exists for the environment. 
There is no consideration of safe pesticide 
limits at landscape scales. For example, 
statistics about the use of neonicotinoids in 
the United Kingdom suggest that the 
landscape-scale dose increased by a factor 
of four between 2000 and 2014 (14). 
Without knowledge of safe environmental 
limits, the total pesticides used — and 
therefore the total environmental dose — is 
governed by market demand rather than by 
a limit on what the environment can endure. 
There is little information about where, 
when, and why pesticides have been used, 
making it very difficult to quantify potential 
environmental effects.  
 
An essential step for pesticide regulation in 
the future is to develop an equivalent to 
pharmacovigilance — perhaps called 
pesticidovigilance. Such a system would 
place responsibility for monitoring the use 
and effects of these chemicals on 
manufacturers and growers by applying 
preregistered designs for how data should 
be collected. It would improve decisions 
concerning approved use and would avoid 
sole reliance on ad hoc studies and sparse 
data. New methods of precision farming 
provide opportunities for new data flows. 
This would also address issues of 
environmental justice by placing the 
responsibility for active management of 
pesticide dosing on those who benefit 
directly and who have the capacity to adapt 
and innovate. It would be a foundation for 
defining best practice, allowing the level of 
precaution applied in regulation to be scaled 
to the level of knowledge about the effects 
of the pesticides. Such a system would 
promote genuinely risk-based pesticide use 
that would make the trade-offs between the 
environmental costs and food production 
more explicit. In specific circumstances 
where there are strong reasons for 
protecting a vital crop, a risk-based system 
could even allow some chemicals currently 
banned under the present systems of 
regulation to be used. 
 
The better alignment of pesticide use with 
this kind of best practice is in everybody’s 
interest. It has the potential to increase trust 
and to sustain the use of important chemical 
technologies. The current assumption 
underlying pesticide regulation — that 
chemicals that pass a battery of tests in the 
laboratory or in field trials are 
environmentally benign when they are used 
at industrial scales — is false. Future 
regulation to deal with this issue may have 
to vary regionally because of differing cost-
benefit analyses, but the effects of dosing 
whole landscapes with chemicals have been 
largely ignored by regulatory systems. This 
can and should be changed.
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Table: How pharmaceuticals and pesticides are regulated  
During early stages of discovery and testing, pharmaceuticals and pesticides are regulated in a 
similar way, but in the later stages and after approval, pharmaceuticals are monitored far more 
effectively.  
 
 Pharmaceuticals Pesticides 
Substance 
discovery and 
development 
 
Search for and synthesize molecules; perform biological tests and 
screening to determine biological activity; determine commercial 
prospects (e.g., potential for patents). 
Preclinical and 
pre-field testing 
 
Conduct safety, efficacy, and toxicological tests using in vitro and in 
vivo laboratory trials and computer modelling. 
Clinical and field 
testing 
 
Test effectiveness, determine 
safety, and identify side effects 
using three levels of trials [phase I 
(first in human), II, and III] with 
increasing patient numbers. 
Test effectiveness, toxicology, 
fate, and behaviour in the 
environment using laboratory and 
field trials. No equivalent to the 
phased trials used in 
pharmaceutical testing. 
Registration and 
approval 
 
Submit development study results on efficacy, effectiveness, safety, 
toxicology, fate, and behaviour to regulatory body for license approval. 
Post-approval 
marketing, use, 
and monitoring 
Once licensed, the substance can 
be used in accordance with the 
product label. Long-term 
monitoring starts (phase IV) to 
determine unexpected effects in 
different categories of people and 
the population more generally 
(using national and global 
reporting systems and 
pharmacovigilance regulations). 
Once licensed, the substance can 
be used in accordance with the 
product label (MRL monitoring 
checks compliance with product 
label to protect human health). Ad 
hoc reporting of incidents or 
effects. No post- approval or long-
term monitoring of effects and no 
equivalent to pharmacovigilance. 
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